Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 241,283 shares of the medical equipment provider's stock after purchasing an additional 10,264 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.10% of Hologic worth $17,462,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic during the 4th quarter valued at approximately $27,000. Venturi Wealth Management LLC bought a new position in shares of Hologic during the 3rd quarter valued at approximately $29,000. NBC Securities Inc. bought a new position in shares of Hologic during the 3rd quarter valued at approximately $33,000. Deseret Mutual Benefit Administrators grew its position in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its position in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 227 shares during the period. 94.73% of the stock is owned by institutional investors.

Insider Activity at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company's stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Scott T. Garrett sold 16,441 shares of the business's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares of the company's stock, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Up 0.1 %

Hologic stock traded up $0.07 during trading hours on Friday, reaching $75.02. The stock had a trading volume of 1,451,370 shares, compared to its average volume of 1,389,154. The stock has a market cap of $17.51 billion, a PE ratio of 38.28, a PEG ratio of 2.49 and a beta of 1.01. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The company has a fifty day simple moving average of $76.25 and a 200-day simple moving average of $73.66.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company's revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.06 EPS. Analysts forecast that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on HOLX shares. UBS Group upped their price target on shares of Hologic from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, February 2nd. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Friday, May 3rd. JPMorgan Chase & Co. increased their target price on shares of Hologic from $85.00 to $91.00 and gave the stock an "overweight" rating in a research note on Friday, May 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research note on Friday, May 3rd. Finally, Evercore ISI increased their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an "in-line" rating in a research note on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and an average price target of $85.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.